AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17899340 — intervention group
Group type: COMPARATOR
Intervention: No instructions during retrieval
Number of subjects: 5
Study 17129308 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lavender oil aromatherapy (2 drops of 2% lavender oil with supplemental oxygen)
Number of subjects: 50
Study 17129308 — intervention group
Group type: COMPARATOR
Intervention: Control group (supplemental oxygen with no lavender oil)
Number of subjects: 50
Study 14664471 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA), 20 mg daily subcutaneous injections
Number of subjects: 251
Study 14664471 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 months followed by GA
Number of subjects: 251
Study 11094039 — intervention group
Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 (5 mg once daily)
Number of subjects: 453
Study 11094039 — intervention group
Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 (7.5 mg once daily)
Number of subjects: 453
Study 11094039 — intervention group
Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 (10 mg once daily)
Number of subjects: 453
Study 11094039 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (100 IU/kg twice daily)
Number of subjects: 453
Study 11094039 — intervention group
Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540
Number of subjects: 453
Study 11094039 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 453
Study 11094039 — intervention group
Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 and Dalteparin
Number of subjects: 453
Study 8747098 — intervention group
Group type: COMPARATOR
Intervention: Sugar ingestion
Number of subjects: 0
Study 8747098 — intervention group
Group type: COMPARATOR
Intervention: Candy or chocolate consumption
Number of subjects: 0
Study 8747098 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-oriented treatment
Number of subjects: 0
Study 2056362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.05 mg/kg)
Number of subjects: 60
Study 2056362 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 60
Study 2056362 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.25 mg/kg)
Number of subjects: 60
Study 6624809 — intervention group
Group type: EXPERIMENTAL
Intervention: Picenadol (LY 150720), 25 mg
Number of subjects: 3
Study 6624809 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine, 100 mg
Number of subjects: 3
Study 6624809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 29716398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 52
Study 29716398 — intervention group
Group type: COMPARATOR
Intervention: Context of treatment (research vs community)
Number of subjects: 52
Study 30917811 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-h Youth MHFA course
Number of subjects: 384
Study 30917811 — intervention group
Group type: COMPARATOR
Intervention: 15-h Australian Red Cross Provide First Aid course
Number of subjects: 384
Study 29083323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylguanidino valeric acid (DMGV) levels
Number of subjects: 0
Study 29083323 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedure cardiometabolic parameters
Number of subjects: 0
Study 26872366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered-cuff endotracheal tube
Number of subjects: 109
Study 26872366 — intervention group
Group type: COMPARATOR
Intervention: Spherical-cuff endotracheal tube (Control)
Number of subjects: 109
Study 24598085 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative care service
Number of subjects: 105
Study 24598085 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 22997340 — intervention group
Group type: EXPERIMENTAL
Intervention: Disrupted reconsolidation through extinction training
Number of subjects: 0
Study 22997340 — intervention group
Group type: COMPARATOR
Intervention: Reactivation of conditioned fear memory
Number of subjects: 0
Study 20812879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 and 450 mg/day)
Number of subjects: 2061
Study 17659605 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 71
Study 17659605 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily
Number of subjects: 71
Study 17659605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 15868384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprinocarsen (2 mg/kg continuous iv infusion on days 1-14, every 21 days) + Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Number of subjects: 18
Study 15868384 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Number of subjects: 18
Study 15868384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprinocarsen + Gemcitabine + Cisplatin
Number of subjects: 18
Study 15868384 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + Cisplatin
Number of subjects: 18
Study 17109676 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.15 microg/kg/week
Number of subjects: 61
Study 17109676 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.30 microg/kg/week
Number of subjects: 61
Study 17109676 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.45 microg/kg/week
Number of subjects: 61
Study 10506601 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with AFM
Number of subjects: 425
Study 8900778 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Nursing Organization (CNO) model
Number of subjects: 0
Study 1855763 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg once daily)
Number of subjects: 237
Study 1855763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 6349715 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-depleted platelet concentrates (PC)
Number of subjects: 98
Study 6349715 — intervention group
Group type: COMPARATOR
Intervention: Standard pooled platelet concentrates (PC)
Number of subjects: 98
Study 6349715 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-depleted PC
Number of subjects: 98
Study 6349715 — intervention group
Group type: COMPARATOR
Intervention: Standard PC
Number of subjects: 98
Study 30957341 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP + EUC
Number of subjects: 135
Study 30957341 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 135
Study 30168228 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based 8-week exercise training programme (walking and activity increase with pedometer)
Number of subjects: 33
Study 30168228 — intervention group
Group type: COMPARATOR
Intervention: General recommendations to walk more (Control group)
Number of subjects: 33
Study 27069360 — intervention group
Group type: EXPERIMENTAL
Intervention: Puer tea extract (PTE) 3 g/day
Number of subjects: 59
Study 27069360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 25043321 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (10 weeks)
Number of subjects: 62
Study 25043321 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BBAT) (10 weeks)
Number of subjects: 62
Study 25043321 — intervention group
Group type: COMPARATOR
Intervention: Control group (single consultation with advice on physical activity)
Number of subjects: 62
Study 22483196 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning therapy (reading aloud and solving simple calculations)
Number of subjects: 64
Study 22483196 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 64
Study 20128828 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless procedure
Number of subjects: 16
Study 20128828 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap procedure
Number of subjects: 16
Study 18094894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive with placebo (levonorgestrel and ethinyl estradiol)
Number of subjects: 33
Study 18094894 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive with estriol (levonorgestrel and ethinyl estradiol)
Number of subjects: 33
Study 15809663 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 18.5
Number of subjects: 49165
Study 15809663 — intervention group
Group type: COMPARATOR
Intervention: BMI 18.5-21.9 (reference)
Number of subjects: 49165
Study 15809663 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 22-24.9
Number of subjects: 49165
Study 15809663 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25.0-27.9
Number of subjects: 49165
Study 15809663 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 28.0-29.9
Number of subjects: 49165
Study 15809663 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30.0-34.9
Number of subjects: 49165
Study 15809663 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI >= 35.0
Number of subjects: 49165
Study 12296779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 76
Study 12296779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 76
Study 12296779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan
Number of subjects: 76
Study 12296779 — intervention group
Group type: COMPARATOR
Intervention: Control fluoride
Number of subjects: 76
Study 9917438 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (750 mg once daily)
Number of subjects: 152
Study 9917438 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (250 mg three times a day)
Number of subjects: 152
Study 7493209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training program
Number of subjects: 100
Study 7493209 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 100
Study 31147378 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-created educational intervention (12 interactive sessions, 2 hours each, from November 2013 to April 2014)
Number of subjects: 24
Study 31147378 — intervention group
Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 24
Study 30412222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50mg/day)
Number of subjects: 0
Study 30412222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25663609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary total antioxidant capacity (upper quintile)
Number of subjects: 7447
Study 25663609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of all studied vitamins
Number of subjects: 7447
Study 25304727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) + interferon-α (IFN-α)
Number of subjects: 310
Study 25304727 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 310
Study 22789797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical containing Orthosiphon stamineus
Number of subjects: 0
Study 22789797 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium-channel blockers or angiotensin converting enzyme inhibitors)
Number of subjects: 0
Study 19786345 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 315
Study 19786345 — intervention group
Group type: COMPARATOR
Intervention: Routine oncology care
Number of subjects: 315
Study 17479929 — intervention group
Group type: EXPERIMENTAL
Intervention: Show-up identification
Number of subjects: 160
Study 17479929 — intervention group
Group type: COMPARATOR
Intervention: Line-up identification
Number of subjects: 160
Study 15499224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month formulation
Number of subjects: 131
Study 15499224 — intervention group
Group type: COMPARATOR
Intervention: 28-day formulation
Number of subjects: 131
Study 11495171 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 238
Study 11495171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study 9498316 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI)
Number of subjects: 110
Study 9498316 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma History Questionnaire (THQ)
Number of subjects: 110
Study 7991130 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT1 nerves
Number of subjects: 0
Study 7991130 — intervention group
Group type: COMPARATOR
Intervention: Other causes of neuropathy (matched control group)
Number of subjects: 0
Study 2846480 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfractionated radiation (3 times a day to a total dose of 4760 cGy)
Number of subjects: 76
Study 2846480 — intervention group
Group type: COMPARATOR
Intervention: Standard daily treatment (to 4000 cGy)
Number of subjects: 76
Study 2846480 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfractionated radiation
Number of subjects: 76
Study 2846480 — intervention group
Group type: COMPARATOR
Intervention: Standard daily treatment
Number of subjects: 76
Study 4919554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Cyclokapron) 1 g four times a day for the first four days of menstruation
Number of subjects: 0
Study 4919554 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 30781758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prev@cib program (experimental group)
Number of subjects: 660
Study 30781758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study 28357598 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser; 1.2 W
Number of subjects: 0
Study 28357598 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser; 0.5 W
Number of subjects: 0
Study 28357598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 0
Study 28357598 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial dentin groups (all treatments)
Number of subjects: 0
Study 24750286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-family partnership intervention
Number of subjects: 61
Study 24750286 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 61
Study 23803136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg initial dose, followed by 75 mg/day for 90 days) plus aspirin (75 mg/day for 21 days)
Number of subjects: 5170
Study 23803136 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75 mg/day for 90 days)
Number of subjects: 5170
Study 23803136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin group
Number of subjects: 5170
Study 23803136 — intervention group
Group type: COMPARATOR
Intervention: Aspirin group
Number of subjects: 5170
Study 21693699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10 mg/20 mg in the morning (within 1 hour of breakfast)
Number of subjects: 171
Study 21693699 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe/simvastatin 10 mg/20 mg in the evening (within 1 hour of dinner)
Number of subjects: 171
Study 18300746 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) treatment
Number of subjects: 47
Study 18300746 — intervention group
Group type: COMPARATOR
Intervention: Isotonic NaCl (control)
Number of subjects: 47
Study 16608780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 0.75 g loading dose before surgery and 250 mg/h during surgery (total 1.5 g)
Number of subjects: 76
Study 16608780 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 76
Study 16608780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 76
Study 16608780 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TA) and Saline solution (control)
Number of subjects: 76
Study 14600575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent interleukin-2 (IL-2) therapy
Number of subjects: 15
Study 12847572 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 0
Study 12847572 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin standard formulation
Number of subjects: 0
Study 8782296 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurume solution with 1% albumin (group 2)
Number of subjects: 47
Study 8782296 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution with 1% albumin (group 4)
Number of subjects: 47
Study 8782296 — intervention group
Group type: COMPARATOR
Intervention: Kurume solution without albumin (group 1)
Number of subjects: 47
Study 8782296 — intervention group
Group type: COMPARATOR
Intervention: GIK solution without albumin (group 3)
Number of subjects: 47
Study 8782296 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with albumin (group 2 and group 4)
Number of subjects: 47
Study 1729820 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol (Isovue‐370)
Number of subjects: 20
Study 1729820 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol (Optiray‐320)
Number of subjects: 20
Study 1729820 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque‐350)
Number of subjects: 20
Study 1729820 — intervention group
Group type: COMPARATOR
Intervention: All contrast media
Number of subjects: 20
Study 6148872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (mean dosage, 87 +/- 43 mg/day)
Number of subjects: 20
Study 6148872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31903773 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised educational sessions for carers
Number of subjects: 197
Study 31903773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 197
Study 30632333 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 strand double modified Kessler repair with 1 knot
Number of subjects: 100
Study 30632333 — intervention group
Group type: COMPARATOR
Intervention: 4 strand double modified Kessler repair with 2 knot
Number of subjects: 100
Study 27093774 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled operator using three-step etch-and-rinse (Optibond FL)
Number of subjects: 42
Study 27093774 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled operator using one-step self-etch (G-Bond)
Number of subjects: 42
Study 27093774 — intervention group
Group type: COMPARATOR
Intervention: Unexperienced operators using three-step etch-and-rinse (Optibond FL)
Number of subjects: 42
Study 27093774 — intervention group
Group type: COMPARATOR
Intervention: Unexperienced operators using one-step self-etch (G-Bond)
Number of subjects: 42
Study 24820248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week meditation program
Number of subjects: 0
Study 24820248 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 22574370 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic varicocelectomy (MV)
Number of subjects: 72
Study 22574370 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic varicocelectomy (LV)
Number of subjects: 72
Study 22574370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MV and LV
Number of subjects: 72
Study 21031578 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV1.tMCK.hSGCA (3.25 × 10¹¹ vector genomes)
Number of subjects: 3
Study 21031578 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 3
Study 18575278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 210
Study 18575278 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 210
Study 18575278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study 15031448 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing film-focus distance (FFD) from 100 cm to 130 cm
Number of subjects: 0
Study 15031448 — intervention group
Group type: COMPARATOR
Intervention: FFD of 100 cm
Number of subjects: 0
Study 12368364 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5-50 mg/day)
Number of subjects: 30
Study 12368364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spironolactone)
Number of subjects: 30
Study 9848801 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple tailored letters with self‐help guide
Number of subjects: 752
Study 9848801 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple tailored letters only
Number of subjects: 752
Study 9848801 — intervention group
Group type: EXPERIMENTAL
Intervention: a single tailored letter with a self‐help guide
Number of subjects: 752
Study 9848801 — intervention group
Group type: EXPERIMENTAL
Intervention: a single tailored letter only
Number of subjects: 752
Study 9848801 — intervention group
Group type: COMPARATOR
Intervention: nontailored intervention
Number of subjects: 752
Study 7862911 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 48
Study 7862911 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide (400 mg)
Number of subjects: 48
Study 7862911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2570234 — intervention group
Group type: EXPERIMENTAL
Intervention: Early suckling
Number of subjects: 4227
Study 2570234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early suckling)
Number of subjects: 4227
Study 322921 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg/day for 6 weeks)
Number of subjects: 10
Study 322921 — intervention group
Group type: COMPARATOR
Intervention: Alpha methyldopa (1.0 gm) with benserazide (1.5 gm)
Number of subjects: 10
Study 28650189 — intervention group
Group type: EXPERIMENTAL
Intervention: Value LAP condition during low intensity exercise
Number of subjects: 0
Study 28650189 — intervention group
Group type: COMPARATOR
Intervention: Control condition during low intensity exercise
Number of subjects: 0
Study 28650189 — intervention group
Group type: EXPERIMENTAL
Intervention: Value LAP condition during calming amusement park rides
Number of subjects: 0
Study 28650189 — intervention group
Group type: EXPERIMENTAL
Intervention: Value LAP condition during exciting amusement park rides
Number of subjects: 0
Study 28650189 — intervention group
Group type: COMPARATOR
Intervention: Control condition during calming amusement park rides
Number of subjects: 0
Study 28650189 — intervention group
Group type: COMPARATOR
Intervention: Control condition during exciting amusement park rides
Number of subjects: 0